{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-004945","form_type":"8-K","ticker":"ABUS","cik":"0001447028","company_name":"Arbutus Biopharma Corp","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.965092+00:00","generated_at":"2026-06-12T07:48:26.621471+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Arbutus Q2 revenue $4.7M, net loss $17.1M; AB-101 clears NZ regulatory for Phase 1","bullets":["Total revenue $4.7M vs $14.2M YoY on lower Qilu license revenue; net loss $17.1M ($0.10 EPS).","Cash $163.5M; runway into Q1 2025; net cash burn guidance $90-95M for 2023.","AB-729 (imdusiran) Phase 2a data at EASL: mean HBsAg decline ~1.6 log10; four patients reached below LLOQ.","AB-101 (oral PD-L1) received NZ Medsafe approval for Phase 1 after FDA clinical hold; dosing starts Q3 2023.","Melissa Rewolinski appointed to board; Karen Sims promoted to CMO; Christopher Naftzger named GC and CCO."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-004945","json":"https://secwatch.observer/filing/0001171843-23-004945.json","markdown":"https://secwatch.observer/filing/0001171843-23-004945.md","text":"https://secwatch.observer/filing/0001171843-23-004945.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447028/000117184323004945/0001171843-23-004945-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447028/000117184323004945/f8k_080223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T07:48:26.621471+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"82186ba79aba6b112e3658a92c016c39dd2685f9","claim":"Arbutus Biopharma Corp reported financial results for second quarter ended June 30, 2023.","evidence_excerpt":"On August 3, 2023, Arbutus Biopharma Corporation (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2023 and certain other information. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated by reference herein.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184323004945/0001171843-23-004945-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}